Compare PRAA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAA | PLRX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | 170 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 639.1M | 81.1M |
| IPO Year | 2002 | 2020 |
| Metric | PRAA | PLRX |
|---|---|---|
| Price | $18.40 | $1.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $24.50 | $2.67 |
| AVG Volume (30 Days) | 351.1K | ★ 550.5K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,201,837,000.00 | N/A |
| Revenue This Year | $2.01 | N/A |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.83 | N/A |
| 52 Week Low | $10.25 | $1.09 |
| 52 Week High | $19.83 | $1.95 |
| Indicator | PRAA | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.65 | 51.70 |
| Support Level | $16.60 | $1.12 |
| Resistance Level | $18.68 | $1.36 |
| Average True Range (ATR) | 0.71 | 0.07 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 86.25 | 66.67 |
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.